SCHEMBL860120

SCHEMBL860120

O=C1NC(=O)C(=Cc2cnn3ccc(Nc4cccc(OCCN5CCOCC5)c4)nc23)N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.42
BTK Q06187 1/20 0.42
SRC P12931 1/20 0.41
SYK P43405 2/20 0.41
HPGD P15428 1/20 0.39
ITK Q08881 2/20 0.39
AURKA O14965 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
TTK P33981 1/20 0.39
AURKB Q96GD4 1/20 0.39
EPHX2 P34913 3/20 0.39
CSNK2A2 P19784 2/20 0.39
GRK2 P25098 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
MAPK14 Q16539 1/20 0.38
PRKCQ Q04759 1/20 0.38
KDR P35968 1/20 0.37
AIMP2 Q13155 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL860119 1.00 EGFR (0.42) EGFRBTKSRCSYKHPGD
SCHEMBL12979116 1.00 EGFR (0.42) EGFRBTKSRCSYKHPGD
SCHEMBL851877 0.86 EGFR (0.48) EGFRBTKSRCSYKITK
SCHEMBL860165 0.86 JAK3 (0.40) AURKACCNA2CDK2CSNK2A2KDR
SCHEMBL13020870 0.86 JAK3 (0.40) AURKACCNA2CDK2CSNK2A2KDR
SCHEMBL860166 0.86 JAK3 (0.40) AURKACCNA2CDK2CSNK2A2KDR
SCHEMBL12645628 0.80 EGFR (0.45) EGFRBTKSRCSYKITK
SCHEMBL860980 0.80 FYN (0.39) HPGD
SCHEMBL12979109 0.80 FYN (0.39) HPGD
SCHEMBL860979 0.80 FYN (0.39) HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
EP-2432473-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 EGFR 624/4885BTK 59/4885SRC 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.